Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Sloan Ratio % : 0.00% (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Clarus Therapeutics Holdings's Sloan Ratio for the quarter that ended in Jun. 2022 was 0.00%.

As of Jun. 2022, Clarus Therapeutics Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Clarus Therapeutics Holdings Sloan Ratio % Historical Data

The historical data trend for Clarus Therapeutics Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Sloan Ratio % Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Sloan Ratio %

237.05

6.18

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Sloan Ratio %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Clarus Therapeutics Holdings's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Sloan Ratio % falls into.

Clarus Therapeutics Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Clarus Therapeutics Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2021 )	-	Cash Flow from Operations (A: Dec. 2021 )
	-	Cash Flow from Investing (A: Dec. 2021 ))	/	Total Assets (A: Dec. 2021 )
	=	(-40.617	-	-43.786
	-	-0.025)	/	51.708
	=	6.18%

Clarus Therapeutics Holdings's Sloan Ratio for the quarter that ended in Jun. 2022 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Jun. 2022 )
	=	(-32.635	-	-56.62
	-	-0.015)	/	48.94
	=	49.04%

Clarus Therapeutics Holdings's Net Income for the trailing twelve months (TTM) ended in Jun. 2022 was -2.769 (Sep. 2021 ) + -4.302 (Dec. 2021 ) + -14.87 (Mar. 2022 ) + -10.694 (Jun. 2022 ) = $-32.64 Mil.
Clarus Therapeutics Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2022 was -12.517 (Sep. 2021 ) + -9.334 (Dec. 2021 ) + -17.268 (Mar. 2022 ) + -17.501 (Jun. 2022 ) = $-56.62 Mil.
Clarus Therapeutics Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 was 0 (Sep. 2021 ) + -0.005 (Dec. 2021 ) + -0.01 (Mar. 2022 ) + 0 (Jun. 2022 ) = $-0.02 Mil.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2022, Clarus Therapeutics Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Clarus Therapeutics Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402